Stockscreener 앱 받기
0.341
8.12%
0.0256
Bioxcel Therapeutics Inc 주식(BTAI)의 최신 뉴스
Bioxcel therapeutics CEO sells shares worth $1,131 By Investing.com - Investing.com Australia
Bioxcel therapeutics' chief scientific officer sells $151 worth of stock By Investing.com - Investing.com Canada
Bioxcel therapeutics CFO Richard Steinhart sells $206 in stock - Investing.com India
Bioxcel therapeutics executive sells $153 in stock - Investing.com
Bioxcel therapeutics CEO sells shares worth $1,131 - Investing.com
Bioxcel therapeutics exec sells $58 in stock By Investing.com - Investing.com UK
BioXcel Therapeutics stock hits 52-week low at $0.35 - Investing.com India
BioXcel Therapeutics (STU:BX2) 5-Day RSI : 7.74 (As of Dec. 05, 2024) - GuruFocus.com
BioXcel Therapeutics stock hits 52-week low at $0.4 By Investing.com - Investing.com Canada
BioXcel Therapeutics stock hits 52-week low at $0.4 - Investing.com India
BioXcel Therapeutics announces pricing of $7M public offering - MSN
BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia
BioXcel Therapeutics Prices of $7 Million Public Offering - citybiz
BioXcel Therapeutics stock hits 52-week low at $0.5 - Investing.com India
BioXcel Therapeutics announces $7M public offering - Hartford Business Journal
BioXcel Prices New Offering - Baystreet.ca
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering - GlobeNewswire
BioXcel Therapeutics Announces $7M Public Offering at $0.48 Per Share with Warrants | BTAI Stock News - StockTitan
BioXcel Therapeutics amends credit agreement, issues new warrants - Investing.com
BioXcel Therapeutics amends credit agreement, issues new warrants By Investing.com - Investing.com Canada
BioXcel Therapeutics Announces Proposed Public Offering - GlobeNewswire
BioXcel Therapeutics Announces Proposed Public Offering - Benzinga
BioXcel Therapeutics Launches Public Offering to Fund Critical Clinical Trials | BTAI Stock News - StockTitan
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript - MSN
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates - MSN
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and Financial Adjustments - GuruFocus.com
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... By GuruFocus - Investing.com Canada
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... - Yahoo Finance
BioXcel Therapeutics Inc. (BTAI) Quarterly 10-Q Report - Quartzy
BioXcel Therapeutics Reports Q3 2024 Financial Results - TipRanks
500: Something went wrong - Investing.com India
Earnings call: BioXcel Therapeutics reports Q3 2024 financials - Investing.com
Earnings call: BioXcel Therapeutics reports Q3 2024 financials By Investing.com - Investing.com UK
BioXcel Therapeutics earnings beat by $0.19, revenue fell short of estimates - Investing.com Canada
BioXcel Therapeutics Inc Reports Q3 2024 Earnings: Net Revenue a - GuruFocus.com
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire
BioXcel Q3 Revenue Drops 37%, but Net Loss Narrows Significantly to $13.7M | BTAI Stock News - StockTitan
Critical Survey: Emergent BioSolutions (NYSE:EBS) vs. BioXcel Therapeutics (NASDAQ:BTAI) - Defense World
What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings - GuruFocus.com
BioXcel Therapeutics (BTAI) Set to Announce Earnings on Thursday - Defense World
BioXcel advances trials for acute agitation treatments - Investing.com India
BioXcel advances trials for acute agitation treatments By Investing.com - Investing.com UK
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia - The Manila Times
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of - GlobeNewswire
BioXcel's Phase 3 Breakthrough: First Patient Enrolled in Critical Agitation Treatment Trial | BTAI Stock News - StockTitan
2.88%
2.65%
자본화:
|
볼륨(24시간):